Cancer and fibrosis therapy developer Forbius has agreed to be acquired by Bristol Myers Squibb nine years after it was spun off by YM BioSciences.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

AI pathology aid developer Medmain, a Kyushu Universty-aligned startup, will use the capital to support international expansion.

Medical equipment maker Yuanzhi Technology led a $43.5m round that will fund work on BGI-backed YuceBio's TMB biomarker.

Toronto Innovation Acceleration Partners has scored an exit having invested at least twice in cancer and fibrosis therapy developer Forbius.

Novartis and existing investors GV, Kaiser Permanente Ventures and Roche Venture Fund helped the cancer test developer push its total funding past the $500m mark.

The Teva, Allianz and Takeda-backed telehealth technology producer has filed to raise up to $100m in an offering that will be boosted by another $100m from Google.

CR-CP Life Science Fund has led the RSV treatment producer’s latest round, participating alongside new and returning backers including Novo and EMS.

The Athenahealth-backed telehealth software provider took its total funding to $125m in a round led by HLM Venture Partners.

Fukuoka Wajiro, SoftBank and Kyushu Power helped pathology imaging system and software provider Medmain raise $10.3m in its second funding round.